QS Research · Michael Burry's Scion Capital analyst template · 2006
Cue Biopharma, Inc. (CUE)
As of 2026-11-21 · 12/15 boxes filled from SEC filings and market data
Report price $4.15 (close 2026-11-20)
Conclusion: PASS
Conviction low · base case none · downside -79% · upside 0%
At $4.15, Cue Biopharma is priced below its $57.9M of net cash, with a $34.7M market cap, while TTM EBIT is -$138.2M and TTM free cash flow is -$51.2M; the market is therefore assigning little or no positive value to the operating business and is treating the revenue base as non-recurring. The call is PASS because no normalized earnings base exists and the priced cases offer no compensating base case. The downside is -78.8% to $0.88, on -75.0% book value at a compressed P/B of 0.77x (today 0.9x). There is no base case, because no independent peer median or own-history multiple was available and a base at today's multiple would be today's price by construction. The upside is 0.0% to $4.15, the analyst's own upside, with no earnings change given to price it. That leaves the priced asymmetry without a base anchor.
Key numbers
- Share price: $4.15
- Market cap: $34.7M
- Latest financial period: TTM to Sep 30, 2026
- Revenue (TTM): $35.6M
- FCF yield: -147.7%
- Price / book: 0.90x
- Earnings-quality flags (TTM): none flagged
- Revenue growth (latest fiscal year): +195.7%
The 15 boxes
- ✓ 1. Long-form business notes
Cue Biopharma (which filed earlier as Imagen Biopharma, Inc. until 2015-06-19) is a clinical-stage biopharmaceutical company with no product revenue: its revenue line — $3.2M FY2020, $14.9M FY2021, $1.2M FY2022, $5.5M FY2023, $9.3M FY2024, $27.5M FY2025, $35.6M TTM to Sep 2026 — is collaboration, license and option consideration, so the cycle is deal-driven, not demand-driven. Operating income was negative in every year of the six-year span, from -$26.6M (FY2025, the smallest loss) to -$53.2M (FY2022), and the TTM to Sep 2026 shows a -$138.2M operating loss and a -$206.7M net loss. Between the oldest and newest annual report the story moved from an internal oncology lead (CUE-101, in Phase 1 trials in FY2020) to out-licensed oncology (ImmunoScape, November 2025) and a preclinical autoimmune lead (CUE-401), with partner cash — $9.5M from ImmunoScape received in Q4 2025 — now the visible driver inside the $27.5M FY2025 revenue figure.
- ✓ 2. Competitive advantage
Cue Biopharma has no durable, demonstrated advantage: it has never recorded product revenue, has a $368.5M accumulated deficit at FY2025 and cash of $27.1M, and its differentiation claim (Immuno-STAT, a masked TGF-b/IL-2) rests on company belief rather than on margin, price or efficacy evidence. Its only external validation is licensing — BI (April 2025, CUE-501) and IMSCP (November 2025, CUE-100 series) — deals that hand over exclusivity and, in BI's case, bar the company from B cell depletion during the research term. The record shows licensing income that swings year to year ($1.2M FY2022 to $27.5M FY2025) against negative operating income in every year FY2020-FY2025, so there is no operating leverage to point to.
- ✓ 3. 10-Q takeaways
Q3 2026 revenue was $0.1 million versus $2.1 million in Q3 2025 because less BI collaboration work was recognized, while the nine months to Sep 2026 rose to $13.7 million from $5.5 million on a $7.5 million BI preclinical milestone and more BI activity. The quarter's $50.0 million net loss and $47.1 million operating loss are dominated by non-cash stock compensation from RSUs granted July 2026 (G&A $29.8M, R&D $17.0M) plus a $3.4 million non-cash warrant-related revaluation loss, not by any change in commercial activity; the company has never booked product revenue. Cash of $57.9 million at Sep 30 2026 is stated to fund at least the next twelve months, after roughly $28 million of one-time Ascendant license outflows in the nine months. No numeric revenue or earnings guidance is given in either the 10-Q or the same-quarter release, and the risk factors repeat the need for substantial additional capital and dilution.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.